Skip to main navigation Skip to search Skip to main content

Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after Cisplatin

  • Richard J. Gralla
  • , Cindy Rittenberg
  • , Mel Peralta
  • , Linda Lettow
  • , Michele Cronin

Research output: Contribution to journalArticlepeer-review

Abstract

The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.

Original languageEnglish (US)
Pages (from-to)86-91
Number of pages6
JournalOncology (Switzerland)
Volume53
Issue number1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cisplatin
  • Delayed emesis
  • Dexamethasone
  • Ondansetron

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after Cisplatin'. Together they form a unique fingerprint.

Cite this